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Patients were treated consecutively in the University 
Hospitals of Leuven between 2005 and 2014 and their data 
were retrospectively retrieved. PORT MPM patients were 
treated with RT doses up to 64 Gy in 2-Gy fractions. PORT 
NSCLC were treated with RT doses up to 60 Gy in 2-Gy 
fractions. Non-surgical patients were treated with RT doses 
up to 66 Gy in 2.75 Gy sequentially with chemotherapy or up 
to 70 Gy in 2 Gy fractions concurrently with chemotherapy. 
Dyspnea scores (CTCAE 4.03) before and after RT were 
retrieved and delta dyspnea was calculated as the difference 
between the dyspnea after RT (worse at any time point) and 
before RT. For every patient, 2 CT scans were retrieved: 1) 
CT0: a free breathing planning CT scan; 2) CT3M: deep 
inspiration breath-hold diagnostic follow up CT scan 3-6 
months after the end of RT. CT0 and CT3M were non-rigidly 
co-registered in MIM. Differences in Hounsfield Unit (delta 
HU=HU3M-HU0) were represented as the slope of the dose-
dependent delta HU between 0 and 20 Gy (expressed in delta 
HU/Gy). Primary endpoint was delta dyspnea >= 2. Univariate 
and multivariate logistic regression analysis were performed 
in order to identify significant predictors of delta dyspnea >= 
2. A p-value of < 0.05 was considered statistically significant.  
 
Results: Delta dyspnea >= 2 was observed in 10/27 patients 
(37%) in the surgical group and in 7/35 patients (20%) in the 
non-surgical group (chi-square test 3.38, p=0.06). Mean delta 
HU/Gy was higher in the surgical group (1.63 vs. 0.67, t-test: 
p=0.04) (see Figure 1). Outcomes of univariate and 
multivariate analysis are showed in Table 1. The model with 
MLD, mean delta HU/Gy and mean heart dose appears to 
better predict a delta dyspnea >= 2 both in the surgical and 
non-surgical group (although not significant). 
 
 
 
 
Conclusion: Surgical patients after PORT are at higher risk of 
developing clinically relevant dyspnea (with a delta >= 2) and 
have a higher increase in lung density (a surrogate of lung 
damage) compared with non-surgical patients. To strengthen 
this hypothesis, we will investigate radiation toxicity after 
more limited surgery (lobectomy) in NSCLC patients. Results 
will be available by the time of the congress. 
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Purpose or Objective: Purpose Data from prospective 
randomized clinical trials are lacking in the comparison 
between lobectomy (LOB) and stereotactic ablative 
Radiotherapy (SABR) in operable patients (pts) and on-going 
trials have troubles in recruiting. In inoperable pts SABR 
achieves a local control of 64-95% in retrospective and 92-98% 
in prospective trials particularly when over 100 Gy Biological 
Equivalent Dose (BED) is delivered. 
 
Material and Methods: From 2010 to 2014, 187 pts with stage 
I-II NSCLC were treated: 133 were male, 54 female. Mean age 
was 72 years. Cyto-histological prove of NSCLC was available 
in 167/187 (89.3%): 111 pts had adenocarcinoma, 51 
squamous cell carcinoma and 3 other histologies. 133 pts 
(71.1%) had stage T1 NSCLC, and 54 (29.9%) stage II NSCLC. 
Ninety-three (49.8%) pts underwent SABR, while ninety-four 
(50.2%) were submitted to LOB. Pts who underwent SABR 
received to 9-20 Gy/die for 3-7 fractions; BED was superior 
than 100 Gy for all treatments. Response to SABR was 
evaluated according to RECIST criteria and toxicity according 
to CTCAE 4.0 scale. To compare LOB vs SABR, we analyzed 
outcomes in terms of Local Control (LC), Tumor-Specific 
Survival (TSS), Metastasis Free Survival (MFS) and Overall 
Survival (OS) using Kaplan-Meier method and log rank tests to 
evaluate differences in time-to-event outcomes between LOB 
and SABR. 
 
Results: At a mean follow up of 23 months (range 6-67), LOB 
showed a better OS (p <0,014) with a 2- and 5-yr OS of 
67,6±5,9% and 34.6±15,7% for SABR and 84.1±4.8% and 
73.4±6.6% for LOB. SABR achieved the same results in terms 
of LC with a 2 and a 5 years LC of 92±3.2% and 80.8±7.9% 
respectively with a p<0,07. Neither significant difference in 
frequency of distant metastasis nor in TSS was observed 
between the two treatment groups (respectively p< 0.41 and 
p<0.50).. In SABR group only 3 G3 lung toxicities were found. 
No other G3 or G4 acute/late toxicity was found. Toxicity 
was minor in SABR group (1 fatigue G1,1 dyspnoea G1,1 
hemoptysis G1); in surgery group we have recorded 7 atrial 
fibrillation, 2 bleeding,1 with death, e 6 prolonged air leak. 
 
Conclusion: SABR using high doses (BED>100) shows similar 
LC than LOB. Very encouraging results in terms of MFS and 
TSS with very few toxicity and no excess of tumor-related 
deaths are obtained with SABR compared with LOB. OS is 
better in LOB group, apparently being strongly influenced by 
the selection of pts addressed to surgery. 
 
Poster: Clinical track: Upper GI (oesophagus, stomach, 
pancreas, liver)  
 
 
PO-0696  
Prognostic impact of celiac/supraclavicular node metastasis 
in locally advanced oesophageal cancer 
W.K. Cho
1Samsung Medical Center, Radiation Oncology, Seoul, Korea 
Republic of 
1, D. Oh1, Y.C. Ahn1, H. Lee2, Y.M. Shim3, J.I. Zo3, 
J.M. Sun4, M.J. Ahn4, K. Park4 
2Kangbuk Samsung Hospital, Radiation Oncology, Seoul, 
Korea Republic of 
3Samsung Medical Center, Thoracic and Cardiovascular 
Surgery, Seoul, Korea Republic of 
4Samsung Medical Center, Medicine, Seoul, Korea Republic of 
 
Purpose or Objective: Most of trials which established the 
standard treatment of locally advanced oesophageal cancer 
included M0 stage according to the 6th edition of the AJCC 
staging system. Now in the 7th edition of AJCC staging 
system, supraclavicular and celiac lymph node (LN) 
metastasis are no more classified into M1, but considered 
same as other regional LNs. We aimed to evaluate the 
treatment outcomes of NACRT followed by surgery in thoracic 
